Ivan Tancevski’s Post

NOW ONLINE Being overweight after #ColorectalCancer diagnosis might affect your health. Read more in this special report by World Cancer Research Fund 🔓 OPEN ACCESS ➡️https://lnkd.in/gXMKSEuY The influence of adiposity on colorectal cancer prognosis remains poorly characterised. Here, as part of CUP Global, the evidence on post-diagnosis adiposity and colorectal cancer outcomes was systematically synthesised using standardised criteria, and a non-linear dose–response meta-analysis was conducted for the first time. Reverse J-shaped associations were observed between post-diagnosis BMI and all-cause mortality, colorectal cancer-specific mortality, and recurrence. Synthesised studies on other adiposity–outcome associations were limited in number and methodological quality. All evidence was graded as ‘limited—no conclusion’ for the likelihood of causality due to potential methodological limitations, calling for additional well-designed observational studies and intervention trials.

Big news in cancer screening! 🎉 The FDA has just approved a new blood test for colorectal cancer (CRC) screening. This breakthrough "Shield" test by Guardant Health offers a noninvasive alternative to traditional methods like colonoscopies and stool-based tests, making CRC screening more accessible. 🩸 Key points: ~ CRC is the second-leading cause of cancer-related deaths in the U.S. ~ Early detection is crucial, with a 91% five-year survival rate when detected early. ~ Screening rates are currently at 59%, below the 80% goal. ~ The ECLIPSE study demonstrated that the Shield test has 83% sensitivity for CRC detection and 90% specificity for advanced neoplasia. Dr. Daniel Chung from Massachusetts General Hospital highlights the importance of this approval, stating it will close the gap in screening rates and save more lives. Dr. William M. Grady from Fred Fred Hutch Cancer Center emphasizes the test's potential as an alternative for those who avoid current screening options. What are your thoughts on this advancement? How do you think it will impact CRC screening and patient compliance? Read the full article for more details: https://lnkd.in/eBuQdstX Let's discuss! 👇 #HealthcareInnovation #CancerScreening #ColorectalCancer #EarlyDetection #GuardantHealth #MedicalAdvancements #PatientCare

📊 Prostate Cancer Trends in Europe: Key Insights for Future Screening Initiatives 👉 A population-based study across 26 European countries has revealed striking differences in prostate cancer incidence over the past decades, with rates ranging from 46 to 336 per 100,000 men in the mid-2000s. Despite this variation, mortality rates were significantly lower and more stable. The findings point to overdiagnosis influenced by prostate-specific antigen (PSA) testing, emphasizing the urgent need for careful screening strategies that minimize harm. These insights provide a critical baseline for upcoming EU screening initiatives. Read the paper here https://lnkd.in/dZjpmmia #ProstateCancer #Overdiagnosis IARC - International Agency for Research on Cancer / World Health Organization Salvatore Vaccarella

Lung cancer is now the most prevalent cause of cancer-related deaths worldwide - but there’s beacon of hope on the horizon: personalised medicine, which allows treatments to be tailored to each patient’s unique cancer profile. To support Lung Cancer Awareness Month, Porterhouse Medical shines a spotlight on how these medical advances, such as molecular phenotyping, could bring us closer to better outcomes for those people affected by this devastating disease. Read the full article, here: https://lnkd.in/eY7EzzzR #MedComms #HealthcareCommunications #MedEd #LungCancer #PersonalizedMedicine

Risk Stratification in Predicting Esophageal Cancer: A New Paradigm for Managing Barrett’s Esophagus Educational Objectives: 1. Summarize the increasing health system burden of esophageal cancer. 2. Recognize patients at high risk for developing esophageal cancer. 3. Describe diagnostic and prognostic tests that provide actionable information for identifying and managing BE. 4. Explain methods to avoid unnecessary surveillance endoscopies. Visit www.cmezone.com/CU241 1.0 AMA PRA Category 1 Credit™

Lung cancer is a complex disease with diverse patient populations, but precision medicine is opening new doors for patients living with this disease. HER2-mutant non-small cell lung cancer is one example where significant unmet medical needs still exist. Precision medicine offers a tailored approach, focusing on the genomic drivers of each patient’s cancer. This not only enhances treatment efficacy but also provides personalized care and improves overall outcomes. As we observe #PrecisionMedicineAwarenessMonth this November, we strive to develop more efficacious, and better tolerated medicines to help even more people living with cancer. http://spr.ly/6047qrmdB

In recognition of the last day of Multiple Myeloma Awareness Month 🌐💙 we’re placing a spotlight on Flinders University researcher Dr Charlotte Downes, recent recipient of a Flinders Foundation Seed Grant. Dr Downes is hopeful that research focusing on a specific protein expressed on the surface of bone marrow cancer cells could one day lead to improved outcomes for multiple myeloma patients with poor prognosis. Multiple myeloma is an aggressive and incurable blood cancer caused by the uncontrolled proliferation of plasma cells in the bone marrow. “Sadly, multiple myeloma remains an invariably fatal disease with an increasing incidence and high treatment costs,” Dr Downes explains. “Novel therapies are urgently needed to improve the survival and quality of life of patients with multiple myeloma”. Thanks to your support, this grant will enable Dr Downes and her team to work towards better outcomes for patients living with Multiple Myeloma. 👉 Learn more about Dr Downes' research https://bit.ly/49jcWYm #multiplemyelomaawarenessmonth #multiplemyeloma #cancerresearch

The "The Lancet Oncology" July editorial stresses the importance of cancer diagnosis in England, summing up promising results in carcer diagnosis via AI and antigen detection, but the importance of improving cancer treatment based on early detection to support treatment outcome is of utmost global importance. National Cancer Control Plans (NCCPs) need to include a proactive disease detection based on innovative tools as well as to guarantee a nimble patient treatment start once disease is detected. #thelancetoncology #thelancet #cancerdiagnosis #nationalcancercontrolplan  #AI

ICYMI: Get a summary of key updates in lung cancer care. Available free on-demand, our Best of Lung Cancer Conference content features expert-led sessions covering critical advances in research, diagnostics, and patient management. Stay current on the latest standards of care – watch at your convenience! 🎥 https://ow.ly/qJ1o50Uc5Z8 Session highlights include: 🫁 Equity in Care: Strategies to reduce disparities in care for patients across the country. 🧬 Sequencing Systemic Therapy for Lung NETs: Fundamental basis of NENs and how to tailor management in a multidisciplinary team. 🩺 Treating Patients with Anorexia: Interventions for managing anorexia-cachexia syndrome. 💊 Managing Endocrine Toxicities from Immunotherapy: Practical tips for distinguishing between common and life-threatening endocrinopathies, plus treatment and consult strategies. #BoL24 #MedOnc #LungCancer #OncEd

#AACR24 American Association for Cancer Research - Large analysis of 902 patients with advanced #urothelialcarcinoma #bladdercancer from IMvigor211 Phase-3 #clinicaltrial: combination of readily available baseline + early-on-treatment (~3 weeks after starting therapy) routine clinical & laboratory variables robustly prognostic (AUC 0.83) for progression as best response (absolutely refractory disease) in patients receiving salvage atezolizumab (PD-L1 inhibitor #Immunotherapy)-can we use such affordable and readily available markers to 1) switch or intensify therapy before clinical progression and deterioration of the patient? 2) can incorporating molecular variables further improve performance of this metric? Pleased to collaborate from AdventHealth Central Florida #cancer Institute with Dana-Farber Cancer Institute Harvard Medical School #DrFranziskaMichor #ChrisGraser